Article
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
Brain pathology (Zurich, Switzerland) - 1 May 2020
Yang Rui Ryan, Shi Zhi-Feng, Zhang Zhen-Yu, Chan Aden Ka-Yin, Aibaidula Abudumijiti, Wang Wei-Wei, Kwan Johnny Sheung Him, Poon Wai Sang, Chen Hong, Li Wen-Cai, Chung Nellie Yuk-Fei, Punchhi Gopika, Chu William Ching-Yuen, Chan Ivan Sik-Hei, Liu Xian-Zhi, Mao Ying, Li Kay Ka-Wai, Ng Ho-Keung
Abstract excerpt
In the 2016, WHO classification of tumors of the central nervous system, isocitrate dehydrogenase (IDH) mutation is a main classifier for lower grade astrocytomas and IDH-mutated astrocytomas is now regarded as a single group with longer survival. However, the molecular and clinical heterogeneity among IDH mutant lower grade (WHO Grades II/III) astrocytomas have only rarely been investigated. In this study, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.